Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Aldx save search
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Published: 2024-01-04 (Crawled : 13:30) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.9%
H: 1.18%
C: -1.18%
update therapeutics platform
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
Published: 2023-12-18 (Crawled : 23:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 1.32%
H: 3.27%
C: -3.27%
adx-629 conference dermatitis trial therapeutics results
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Applied Digital Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLD
Published: 2023-09-09 (Crawled : 20:20) - prnewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
| Email alert
Add to watchlist
APLD | $2.465 3.14% 3.04% 3.2M
|
Manufacturing
| Email alert
Add to watchlist
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
| Email alert
Add to watchlist
corporation deadline trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages KeyCorp Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KEY
Published: 2023-08-25 (Crawled : 00:20) - prnewswire.com
KEY | $14.63 1.74% 0.0% 17M
|
Finance
| Email alert
Add to watchlist
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
| Email alert
Add to watchlist
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
| Email alert
Add to watchlist
deadline trial
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
Published: 2023-06-29 (Crawled : 12:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -0.91%
H: 3.92%
C: 3.13%
trial therapeutics
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa
Published: 2023-06-28 (Crawled : 22:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -0.67%
H: 6.07%
C: 4.32%
adx-2191 conference trial therapeutics results
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough
Published: 2023-06-27 (Crawled : 12:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 1.2%
H: 5.26%
C: -1.84%
trial therapeutics
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough
Published: 2023-06-26 (Crawled : 22:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -0.98%
H: 10.16%
C: 6.68%
conference trial therapeutics results
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Published: 2023-05-23 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: -0.62%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -1.22%
GKOS | $96.5 1.44% 0.0% 700K
|
Health Technology
|
| O: -0.71%
H: 2.06%
C: -1.05%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -2.27%
H: 4.24%
C: -2.21%
ALC | $79.55 1.38% -0.25% 1.1M
|
Health Technology
|
| O: -0.51%
H: 0.02%
C: -3.25%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.31%
H: 0.26%
C: -1.34%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
OCUL | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
|
| O: 4.45%
H: 7.65%
C: 2.21%
GRFS | News | $6.29 -3.82% -3.97% 1.2M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -3.74%
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.61%
pharma disease pipeline set eye trial
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
Published: 2023-04-13 (Crawled : 12:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.9%
H: 8.2%
C: 2.58%
trial therapeutics
Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
Published: 2023-04-06 (Crawled : 14:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.0%
H: 2.26%
C: 1.64%
adx-629 dermatitis trial therapeutics phase 2
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
Published: 2023-03-30 (Crawled : 18:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.0%
H: 2.43%
C: 0.53%
adx-629 trial therapeutics phase 2
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -1.79%
H: 5.34%
C: 3.78%
trial therapeutics phase 2
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 1.26%
H: 3.88%
C: -6.24%
reproxalap disease eye trial therapeutics positive results
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
Published: 2023-02-23 (Crawled : 13:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.58%
H: 5.3%
C: 5.3%
trials drug expected therapeutics
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
Published: 2023-02-16 (Crawled : 18:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -1.09%
H: 8.6%
C: 6.62%
trials disease therapeutics phase 2
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
Published: 2022-12-13 (Crawled : 14:20) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: -1.09%
adx-629 alcohol trial phase 2
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
Published: 2022-10-26 (Crawled : 13:20) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.0%
H: 8.0%
C: 7.81%
meeting therapeutics presentation
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 1.61%
H: 2.12%
C: -3.35%
adx-2191 trial therapeutics
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Published: 2022-10-05 (Crawled : 23:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -1.46%
H: 3.9%
C: 3.53%
adx-2191 conference trial therapeutics results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
UHS | $157.47 2.49% 4.13% 900K
|
Health Services
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.